Skip to main content
eXit

ImmunoSensation leaves X

Due to recent developments, we decided to discontinue our activities on the social media plattform X. With this decision, we follow more than 60 german universities and other research institutions. As a Cluster of Excellence, we see the communication of research and scientific results as well as their discussion as one of our tasks, which is why we did not make this decision lightly. However, X's line is not compatible with the basic values that we represent and also want to live in our communication. These include transparency, constructive discourse and, above all, scientific integrity.

We are looking forward to welcome you on our channels at

Bluesky

LinkedIn

Instagram

facebook

youtube

 

Related news

Children in the lab at "Girls' and Boys' Day 2026"

News categories: Outreach

Girls' & Boys' Day at ImmunoSensation³

The annual "Girls' & Boys' Day" (former "Girls' day") sets out to introduce children and young addults to careers their respective gender is still underrepresented in. To celebrate this special day and offer insights into the work of a biomedical researcher, we welcomed students from all over Germany to our laboratories. Besides hands-on science, career options and perspectives in research were discussed.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry
Nora Möhn

News categories: Publication

New Findings on Immunotherapy for a Rare Brain Infection

Progressive multifocal leukoencephalopathy (PML) is a rare but very serious brain disease. It is caused by the reactivation of the widespread JC virus when the immune system is severely weakened. There is currently no targeted antiviral therapy available, which is why new treatment approaches are urgently needed. In recent years, so-called immune checkpoint inhibitors have been increasingly used; these “unlock” the immune system and reactivate the body’s own immune cells. The results were recently published in the journal JAMA Neurology.
View entry

Back to the news overview